This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Peters, U. Articles by Hayes, R. B. Search for Related Content PubMed PubMed Citation Articles by Peters, U. Articles by Hayes, R. B. Related Collections Epidemiology Epidemiology: Nutritional Epidemiology

Serum Lycopene, Other Carotenoids, and Prostate Cancer Risk: a Nested Case-Control Study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

¹ Fred Hutchinson Cancer Research Center; ² University of Washington, Seattle, Washington; ³ Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Rockville, Maryland; ⁴ Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia; ⁵ Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; and ⁶ Nutrition and Cancer Unit, International Agency for Research on Cancer, Lyon, France

Requests for reprints: Ulrike Peters, Cancer Prevention Program, Fred Hutchinson Cancer Research Center, P.O. Box 19024, 1100 Fairview Avenue North M4-B402, Seattle, WA 98109-1024. Phone: 206-667-2450; Fax: 206-667-7850. E-mail: upeters{at}fhcrc.org

Background: Reports from several studies have suggested that carotenoids, and in particular lycopene, could be prostate cancer–preventive agents. This has stimulated extensive laboratory and clinical research, as well as much commercial and public enthusiasm. However, the epidemiologic evidence remains inconclusive.

Materials and Methods: We investigated the association between prediagnostic serum carotenoids (lycopene, -carotene, ß-carotene, ß-cryptoxanthin, lutein, and zeaxanthin) and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, a multicenter study designed to examine methods of early detection and risk factors for cancer. The study included 692 incident prostate cancer cases, diagnosed 1 to 8 years after study entry, including 270 aggressive cases, with regional or distant stage (n = 90) or Gleason score 7 (n = 235), and 844 randomly selected, matched controls. As study participants were selected from those who were assigned to annual standardized screening for prostate cancer, results are unlikely to be biased by differential screening, a circumstance that is difficult to attain under non–trial conditions.

Results: No association was observed between serum lycopene and total prostate cancer [odds ratios (OR), 1.14; 95% confidence intervals (95% CI), 0.82-1.58 for highest versus lowest quintile; P for trend, 0.28] or aggressive prostate cancer (OR, 0.99; 95% CI, 0.62-1.57 for highest versus lowest quintile; P for trend, 0.433). ß-Carotene was associated with an increased risk of aggressive prostate cancer (OR, 1.67; 95% CI, 1.03-2.72 for highest versus lowest quintile; P for trend, 0.13); in particular, regional or distant stage disease (OR, 3.16; 95% CI, 1.37-7.31 for highest versus lowest quintile; P for trend, 0.02); other carotenoids were not associated with risk.

Conclusion: In this large prospective study, high serum ß-carotene concentrations were associated with increased risk for aggressive, clinically relevant prostate cancer. Lycopene and other carotenoids were unrelated to prostate cancer. Consistent with other recent publications, these results suggest that lycopene or tomato-based regimens will not be effective for prostate cancer prevention. (Cancer Epidemiol Biomarkers Prev 2007;16(5):962–8)

This article has been cited by other articles:

				A. Vrieling, D. W Voskuil, J. M Bonfrer, C. M Korse, J. van Doorn, A. Cats, A. C Depla, R. Timmer, B. J Witteman, F. E van Leeuwen, et al. Lycopene supplementation elevates circulating insulin-like growth factor binding protein-1 and -2 concentrations in persons at greater risk of colorectal cancer Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1456 - 1462. [Abstract] [Full Text] [PDF]

				E. Giovannucci Does Prostate-Specific Antigen Screening Influence the Results of Studies of Tomatoes, Lycopene, and Prostate Cancer Risk? J Natl Cancer Inst, July 18, 2007; 99(14): 1060 - 1062. [Full Text] [PDF]

				P. M. Coates Evidence-Based Reviews in Support of Health Policy Decisions J Natl Cancer Inst, July 18, 2007; 99(14): 1059 - 1059. [Full Text] [PDF]